Harel Dahari

Hepatitis C Viral Dynamics in Vivo and the Antiviral Efficacy of Interferon-α Therapy

Avidan U. Neumann, Nancy P. Lam, Harel Dahari et al. · Science · 1998 · 2.1K citations

Pharmacy, Infectious Diseases, Pharmacokinetics +17

Rapid Emergence of Protease Inhibitor Resistance in Hepatitis C Virus

Libin Rong, Harel Dahari, Ruy M. Ribeiro et al. · Science Translational Medicine · 2010 · 359 citations · Full text

Life Sciences, Infectious Diseases, Microbiology +15

Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life

Jérémie Guedj, Harel Dahari, Libin Rong et al. · Proceedings of the National Academy of Sciences · 2013 · 342 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +17

Oral prenylation inhibition with lonafarnib in chronic hepatitis D infection: a proof-of-concept randomised, double-blind, placebo-controlled phase 2A trial

Christopher Koh, Laëtitia Canini, Harel Dahari et al. · The Lancet Infectious Diseases · 2015 · 263 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +12

Antiviral action of ribavirin in chronic hepatitis C

Jean–Michel Pawlotsky, Harel Dahari, Avidan U. Neumann et al. · Gastroenterology · 2004 · 255 citations · Full text

Medicine, Infectious Diseases, Pharmacology +14